Radionuclide Drug Conjugates

Radiopharmaceuticals have proven to be effective agents since they can be successfully applied for both diagnostics and therapy. Radionuclide drug conjugates (RDCs) combine a radioactive compound, a tailored-targeting molecule for specific receptors enriched on diseased cells, and a linker for stable attachment, enabling more effective radiation delivery and significantly reducing side effects by attacking only cancerous cells.

WuXi AppTec has developed a comprehensive workflow for radiopharmaceutical discovery and development, from target selection and ligand ID to stability testing and in vivo efficacy and safety assessment.